drie ab re-investment in r&d and responsible...

2016 DRIVE-AB Conference

Stimulating innovation, sustainable use and global access to antibiotics

PROGRAMME2 JUNE 2016, AMSTERDAM, THE NETHERLANDSThe Royal Netherlands Academy of Arts and Sciences, Tinbergen Room

DRIVE AB RE-INVESTMENT IN R&D AND RESPONSIBLE ANTIBIOTIC USE



2 Stimulating innovation, sustainable use and global access to antibiotics2016 DRIVE-AB Conference Programme

Aim of the conferenceGlobal leaders agree on the need to maintain a steady supply of effective antibiotics for all as a critical part of the strategy to address antibiotic resistance. The questions now are: what are the most effective ways to stimulate the discovery and development of new antibiotics, ensure their access and support their sustainable use? And how can we implement concrete policies to accomplish these goals globally?

This conference will bring together decision makers and policy

experts from around the world to answer these questions.

Through examples of ongoing initiatives, our distinguished

speakers and panellists will explore solutions, focusing on those

that are the most practical and realistic to implement globally.

As part of the discussions, DRIVE-AB will present the preliminary

results of its research and seek feedback from stakeholders

regarding feasibility of the reward models under consideration by

the consortium.

Stakeholders at this conference, including regulatory and public

health experts, economists, and representatives of pharmaceutical

companies and research institutions, all have critical roles

to play in addressing resistance. Their broad engagement

will ensure robust discussion and help DRIVE-AB to deliver

effective recommendations in 2017 with a high probability of

implementation. We will identify concrete actions that conference

delegates may take as part of a coordinated global effort to

address antibiotic resistance.

The event consists of four sessions featuring a keynote address

followed by a panel discussion. At the end of each panel

discussion, the faculty and delegates will work together to create

an ‘agenda for future action’ to identify three concrete actions

that attendees can advocate for to address current gaps in policy.

Delegates are encouraged to consider their responses to the

questions posed during panel discussions and actively contribute

to the discussion.

3Stimulating innovation, sustainable use and global access to antibiotics2016 DRIVE-AB Conference Programme

Programme

June 1PRE-CONFERENCE PROGRAMME

June 2PRELIMINARY AGENDA

1400 - 1800 WP1A pilot interviews of third party stakeholders on barriers to responsible antibiotic use

1900 - 2200 Social event and buffet dinner at NH Amsterdam Centre, Stadhouderskade, 7 1054ES, Amsterdam

0830 - 0900 Registration and Refreshments

0900 - 0905 Welcome Address Judy Hackett, AstraZeneca and DRIVE-AB coordinator, and Jos van der Meer, President European Academies’ Science Advisory Council, Royal Netherlands Academy of Arts and Sciences Chair – Stephan Harbarth, Geneva University Hospitals and Faculty of Medicine and DRIVE-AB coordinator

Session 1: Setting the scene Moderated by Professor Otto Cars, ReAct and DRIVE-AB partner Thissessionwilldiscussthegloballandscapeinthefightagainstantimicrobialresistanceandidentifykeygapsin action, policy or its implementation.

0905 - 0910 Introductions Otto Cars, Founder and senior adviser, ReAct-Action on Antibiotic Resistance, DRIVE-AB partner

0910 - 0930 Keynote: Lessons learned from Dutch interventions to decrease antibiotic use, and future actions that will be taken Angelique Berg, Director-General of Health at the Ministry of Health, Welfare and Sport, The Netherlands

0930 - 1015 Panel Discussion Martin Seychell, European Commission, Directorate-General for Health and Food Safety Marie-Paule Kieny, World Health Organization Suwit Wibulpolprasert, International Health Policy Program, Ministry of Public Health, Thailand Lynn Marks, GSK, Senior Clinical Advisor to the Infectious Disease Therapy Area Unit

1015 - 1030 Agenda for Future Action

1030 - 1100 Refreshments

4 2016 DRIVE-AB Conference ProgrammeStimulating innovation, sustainable use and global access to antibiotics 4

Session 2: Addressing antibiotic innovation together with sustainable use Moderated by Anja Schreijer, Independent Consultant in Antimicrobial Resistance, WHO/Europe This session will explore how antimicrobial stewardship and sustainable use policies can be integrated into new policy interventions, including new economic models, and how current and anticipated trends in antibiotic resistance are influencingpublichealthprioritiesandantibioticinnovation.

1100 - 1105 Introductions Anja Schreijer, Independent Consultant in Antimicrobial Resistance, WHO/Europe

1105 - 1125 Keynote: Current status of global activities on surveillance, responsible use, and new treatments for bacterial infections Dame Sally Davies, Department of Health, England

1125 - 1215 Panel Discussion Inge Gyssens, Radboud University Medical Center and DRIVE-AB partner Yehuda Carmeli, Tel-Aviv Medical Center and DRIVE-AB partner Marc Sprenger, World Health Organization Dominique Monnet, European Centre for Disease Prevention and Control Arjun Srinivasan, U.S. Centers for Disease Control and Prevention Betuel Sigauque, Manhiça Health Research Centre, Mozambique


1230 - 1330 Lunch Break

Session 3: New economic models for antibiotic innovation Moderated by Ramanan Laxminarayan, Center for Disease Dynamics, Economics and Policy, Strathclyde University and DRIVE-AB partner This session will explore a range of incentives and policies designed to stimulate the discovery and development of new antibiotics while ensuring both sustainable use of and appropriate access to antibiotics. Potential challenges to implementing such policies will be considered and discussed.

1330 - 1335 Introductions Ramanan Laxminarayan, Director, Center for Disease Dynamics, Economics and Policy, Strathclyde University and DRIVE-AB partner

1335 - 1400 Keynote: New economic models to stimulate antibiotic innovation, including barriers to and opportunities for integrating sustainable use and access policies John-Arne Røttingen, Norwegian Institute of Public Health and DRIVE-AB partner

1400 - 1445 Panel Discussion Jean-Pierre Paccaud, Drugs for Neglected Diseases initiative and Global Antibiotic Research and Development partnership Shiva Dustdar, European Investment Bank Florence Séjourné, BEAM Alliance Joe Larsen, Biomedical Advanced Research and Development Authority JohnRex,AstraZeneca,SeniorVPandChiefStrategyOfficer,InfectionBusinessUnit


1500 - 1530 Refreshments

Session 4: The way forward Moderated by David Heymann, Chatham House and DRIVE-AB partner Thissessionaimstodefinepriorityactionsformoreeffectivelyaddressingincentivesforinnovationwhileensuring sustainable use of and appropriate access to antibiotics.

1530 - 1535 Introductions David Heymann, Chatham House and DRIVE-AB partner

1535 - 1545 Update: Brief outline of the final recommendations of the UK Review on Antimicrobial Resistance Hala Audi, Review on Antimicrobial Resistance, United Kingdom

1550 - 1655 Panel Discussion Marc Mendelson, Federation of Infectious Diseases Societies of Southern Africa Manica Balasegaram, Médecins Sans Frontières Access Campaign Wiebke Löbker, Federal Joint Committee (G-BA), Germany Christian Brun-Buisson, Ministerial Delegate on AMR, Ministry of Social Affairs and Health, France Julie Gerberding, MSD, Executive Vice President for Strategic Communications, Global Public Policy and Population Health Ursula Theuretzbacher, Center for Anti-Infective Agents, Vienna and DRIVE-AB partner


1700 - 1710 Closing Address John-Arne Røttingen, Norwegian Institute of Public Health and DRIVE-AB partner



DRIVE-AB COORDINATOR

Stephan HarbarthDRIVE-AB coordinator, Associate Professor & Senior Consultant (Médecin adjoint agrégé), Attending in Geriatric and General Infectious Diseases & Associate Hospital Epidemiologist, Geneva University Hospitals

Professor Stephan Harbarth earned in 1993 his medical degree from Ludwig-Maximilians-University in Munich, Germany, and completed his residency in internal medicine and tropical medicine at Munich University Hospitals

After serving as a clinical fellow in the Infectious Diseases

Division in the Department of Internal Medicine at Geneva

University Hospitals, Dr Harbarth completed his master’s degree in

epidemiology at Harvard University in Boston. He is board certified

in infectious diseases and was appointed associate professor at

the University of Geneva in 2010. Dr Harbarth’s work has garnered

several awards. His group is currently conducting several clinical

and epidemiological studies to evaluate key questions related

to the control of the acquisition, transmission and infection

by multidrug-resistant microorganisms. He participates in

several ongoing large-scale EU-funded studies (R-GNOSIS, AIDA,

COMBACTE) and manages the DRIVE-AB project to address this

public health threat.

Notes

7

DRIVE-AB COORDINATOR

Stimulating innovation, sustainable use and global access to antibiotics2016 DRIVE-AB Conference Programme

Judith HackettDRIVE-AB coordinator, Global Payer Evidence Director, AstraZeneca

Judy Hackett received her Pharmacy Degree from the University of Toronto. She subsequently completed her M.B.A. at York University

As well she has a graduate degree in Evaluation and Outcomes

from the Faculty of Medicine, University of Toronto. She began her

career working in community pharmacy and then went onto work

as a payer where she developed and managed drug formularies as

well as evaluated DUR reports. She has worked for over 20 years

in the pharmaceutical industry in the government affairs, health

economics and pricing. Judy is currently Global Payer Evidence

Director at AstraZeneca

Notes


Otto CarsFounder and senior adviser, ReAct-Action on Antibiotic Resistance, DRIVE-AB partner

Professor Otto Cars is a senior professor in Infectious Diseases at Uppsala University, Sweden. He has more than 20 years of experience of working on antibiotic resistance

He runs a research laboratory focussing on in vitro

pharmacodynamics of antibiotics and antibiotic combinations

for MDR bacteria. In 1995, he founded the Swedish Strategic

Programme Against Antibiotic Resistance (Strama) for which he

was chairman until 2011. In 2004, he initiated the international

network Action on Antibiotic Resistance (ReAct), where he holds

the position as senior adviser.

Notes

DRIVE-AB MODERATOR


Anja SchreijerIndependent Consultant in Antimicrobial Resistance, WHO/Europe

Dr Anja Schreijer is an independent Consultant in Infectious Disease control. After obtaining her degree as a medical doctor at the University of Amsterdam and finishing her PhD in Clinical Epidemiology at the university of Leiden and Amsterdam

she specialized in Infectious Disease Control and Public Health

at the Netherlands School of Public and Occupational Health. As

a Senior policy advisor on antimicrobial resistance at the Centre

for Infectious Disease Control (RIVM) she was responsible for the

international activities on AMR. In that context, she was closely

involved in the ministerial meeting on AMR for EU ministers of

Health and Agriculture that took place in Amsterdam on February

10 this year in the light of the current Dutch EU Presidency.

She currently works as an independent consultant with WHO/Euro

on the reduction of inappropriate use of antibiotics in the TAP

project. She also works with the national organization for Public

Health Services in the Netherlands as a project leader on AMR

and she teaches about AMR at the University Medical Centre in

Utrecht and at the Netherlands School of Public and Occupational

Health. She is a member of the AMR programme committee of

the Netherlands organization for health research and

development (ZonMw).

Notes

DRIVE-AB MODERATOR


Ramanan LaxminarayanDirector, Center for Disease Dynamics, Economics and Policy, Strathclyde University and DRIVE-AB partner

Ramanan Laxminarayan directs the Center for Disease Dynamics, Economics & Policy. He is also a Senior Research Scholar and Lecturer at Princeton University

His research deals with the integration of epidemiological models

of infectious diseases and drug resistance into the economic

analysis of public health problems. He has worked to improve

understanding of drug resistance as a problem of managing a

shared global resource.

Laxminarayan has worked with the World Health Organization

(WHO) and the World Bank on evaluating malaria treatment

policy, vaccination strategies, the economic burden of tuberculosis,

and control of non-communicable diseases. He has served on a

number of advisory committees at WHO, the Centers for Disease

Control and Prevention, and the Institute of Medicine. In 2003-

04, he served on the National Academy ofScience/Institute of

Medicine Committee on the Economics ofAntimalarial Drugs and

subsequently helped create the Affordable Medicines Facility for

malaria, a novel financing mechanism for antimalarials. His work

has been covered in major media outlets including Associated

Press, BBC, CNN, the Economist, LA Times, NBC,NPR, Reuters,

Science, Wall Street Journal, and National Journal.

DRIVE-AB MODERATOR

Notes


David HeymannHead and Senior Fellow, Centre on Global Health Security, Chatham House and DRIVE-AB partner

David Heymann is Professor of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine; Head of the Centre on Global Health Security at Chatham House, London and Chairman of the Board, Public Health England

He was previously the WHO’s Assistant Director-General for

Health Security and Environment, and Representative of the

Director-General for polio eradication. In 2009 Prof Heymann was

appointed an honorary Commander of the Most Excellent Order of

the British Empire (CBE) for service to global public health.

Notes

DRIVE-AB MODERATOR

12

Jos van der MeerPresident European Academies’ Science Advisory Council, Royal Netherlands Academy of Arts and Sciences

Jos W.M. van der Meer is professor and chairman at the department of internal medicine of the Radboud University Nijmegen Medical Centre in Nijmegen, Netherlands

He is a member of the Royal Netherlands Academy of Arts and

Sciences (since 2003), of which he is vice president and chairman

of the division of natural sciences (since 2006). He performs

research on cytokines and host defence, chronic fatigue syndrome

and Hyper-IgD syndrome(HIDS). He is also active in graphic art

and makes cartoons, for example for the Dutch science journal

Mediator.

Notes

DRIVE-AB SPEAKER

Stimulating innovation, sustainable use and global access to antibiotics2016 DRIVE-AB Conference Programme


Angelique BergDirector General at Department of Health; ministerie van VWS Representative of the Ministry of Health, Welfare and Sport, The Netherlands

Angelique Berg since 1 January 2015 Director General of Public Health at the Ministry of Health, Welfare and Sport, was previously Director General for Fiscal Affairs at the Ministry of Finance

Before that for one year she was Director General Fiscal Policy

at the Ministry of Finance, where she started her career in 1993.

There she held various positions until her appointment in 2001

as Adviser at the Ministry of General Affairs (portfolio Economic

Affairs, Transport, Water Management and Agriculture). In 2007,

Berg moved to the then Ministry of Housing. There she worked

respectively as Director Local Environmental Quality

and Transport, and as Director Climate and Air Quality.

Notes

DRIVE-AB SPEAKER


Dame Sally DaviesChiefMedicalOfficerDepartmentofHealthEngland

Dame Sally Davies is the Chief Medical Officer for England & Chief Medical Advisor to UK Government. In this role she advises on medical matters with responsibilities for public health and providing leadership to public health directors

She previously founded the National Institute for Health Research

and was the Department of Health’s Chief Scientific Adviser and

Research & Development lead. Sally advises internationally,

including to Singapore A* International Advisory Group, IHME

Board Washington and is on the WHO Executive Board. Her 2013

infectious diseases report brought to light the increasing threat of

AMR calling for global action to address key areas: stewardship;

monitoring/surveillance; antibiotic development. Sally advocates

globally on AMR: in 2013 at a WHA side event, the G8 Science

Ministers’ meeting and the Global Health Security Initiative in

Rome. She chaired the World Innovation Summit for Heath 2013

AMR forum and chairs the AMR Strategic & Technical Advisory

Group to WHO. She raised public awareness of AMR through a

Penguin book and TED talk. Sally is a Fellow of the Royal Society

and member of the National Academy of Medicine.

Notes

DRIVE-AB SPEAKER

14


John-Arne RøttingenDirector, Division of Infectious Disease Control, Norwegian Institute of Public Health and DRIVE-AB partner

Dr John-Arne Røttingen is the Executive Director of Infection Control and Environmental Health at the Norwegian Institute of Public Health; Professor of Health Policy at the Department of Health Management and Health Economics, Institute of Health and Society, University of Oslo; Adjunct Professor at the Department of Global Health and Population, Harvard School of Public Health

He is Associate Fellow at the Centre on Global Health Security,

Chatham House; member of the Scientific Oversight Group of

the Institute for Health Metrics and Evaluation, University of

Washington, Seattle; and member of the International Advisory

Committee for the Global Burden of Disease study. He has been

Director General of the Norwegian Knowledge Centre for the

Health Services; Oxford Scholar at Wadham College; and Fulbright

Fellow at Harvard Kennedy School. He received his MD and PhD

from the University of Oslo, an MSc from Oxford University and an

MPA from Harvard University.

Notes

DRIVE-AB SPEAKER


Hala AudiHead of Review Team, Review on Antimicrobial Resistance, United Kingdom

Hala Audi heads the Review team, on secondment from HM Treasury. Before joining the UK civil service, Hala was an international arbitration lawyer at Skadden, Arps, Slate, Meagher & Flom LLP in New York and London

Advising clients in a range of industries including energy,

construction and financial services. Hala studied law in Paris and

at Columbia University Law School and public administration at

the Kennedy School of Government and the LSE.

Notes

DRIVE-AB SPEAKER


Martin SeychellEuropean Commission, Directorate-General for Health and Food Safety

A graduate in chemistry and pharmaceutical technology, Martin Seychell specialized in chemical analysis. He has held important positions on several government boards and commissions in Malta, including the Food Safety Commission and the Pesticides Board

He occupied the post of Head of Directorate at the Malta

Standards Authority between 2001 and 2006. He has been

responsible for the implementation of a number of EU directives

in the areas of risk assessment, food safety, chemicals and

cosmetic products legislation, and has actively participated

in negotiations on major technical proposals such as the new

chemicals legislation, REACH, and in screening processes in the

areas of free movement of goods, environment and agriculture

during the process leading to Malta’s accession to the EU. He

held the post of Director of Environment in Malta between 2006

and 2011. As Director, he was responsible for a broad range of

functions arising from the Maltese Environment Protection Act. He

was appointed Deputy Director General for Health and Consumers

at the European Commission in March 2011.

Notes

DRIVE-AB PANELLIST

Marie-Paule KienyAssistant Director-General - Health Systems and Innovation World Health Organization

Dr Marie-Paule Kieny is Assistant Director General for Health Systems and Innovation at the World Health Organization. Beginning in 2001, she directed the WHO Initiative for Vaccine Research

Major successes under her leadership were the development

and licensing of new vaccines against meningitis and against

pandemic influenza in developing countries, through pioneering

technology transfer. Vaccines against poverty-related diseases

and those that disproportionately affect poor and marginalized

populations are continuing priorities. Before coming to WHO,

she was Assistant Scientific Director of Transgene S.A. from 1981

to 1988, and Director of Research and Head of the Hepatitis C

Virus Molecular Virology Group at INSERM from 1999 to 2000.

Dr. Kieny received her PhD in microbiology from the University

of Montpelier in 1980 and a Diplôme d’Habilitation à Diriger des

Recherches from the University of Strasbourg in 1995. She has

published over 250 articles and reviews, mainly in the areas of

infectious diseases, immunology and vaccinology.

Notes

DRIVE-AB PANELLIST

18 Stimulating innovation, sustainable use and global access to antibiotics2016 DRIVE-AB Conference Programme18


Suwit WibulpolprasertVice Chair, International Health Policy Program, Ministry of Public Health, Thailand

Suwit Wibulpolprasert, M.D. is a general practitioner, public health specialist, and policy advocator. He was the Director of Food and Drug Administration Technical Division; Director of the Bureau of Health Policy and Planning; Assistant Permanent Secretary and Deputy Permanent Secretary of Ministry of Public Health

His main interests are health policy and planning and global

health. He represented Thailand and the South-east Asian region

as a Member and Vice Chair of the Governing Board of the Global

Fund. He chaired the Global Fund’s Policy and Strategy Committee

in 2010 - 2011.

He served the highest government official rank as a Senior

Advisor in Disease Control to the Ministry of Public Health.

He was appointed as an adviser to the Health Minister on Global

Health in 2014 and adviser to the Bureau of International Health

in 2015. Currently he is Vice-Chair of International Health Policy

Program Foundation and Health Intervention and Technology

Assessment Foundation.

Notes

DRIVE-AB PANELLIST

Lynn MarksMD, Corporate Secretary and Chair of the Oversight Committee, TransCelerate BioPharma, Inc.

Dr Lynn Marks is Senior Clinical Advisor for Infectious Diseases with a particular focus on antimicrobial drug development and the global challenge of antimicrobial resistance

He joined GSK in 1993 in the Infectious Diseases organization

with increasing accountability. Ultimately he led the Infectious

Diseases Therapy area globally. Over the next ten years, his

focus was antivirals, including a large portfolio of anti-HIV

medications, diseases of the developing world in particular

malaria and tuberculosis as well as antibacterials. Subsequently,

he transitioned to lead Projects, Clinical Platforms & Sciences.

In this role, he had operational accountability for clinical trials

over a broad range of disease and therapeutic areas on a global

scale ranging across the Phase I to IV development landscape.

In addition, he helped create TransCelerate BioPharma, Inc.

and currently is the Corporate Secretary and Chair of the

Oversight Committee.

Dr. Marks is Board Certified in Internal Medicine and

Infectious Diseases.

Notes

DRIVE-AB PANELLIST



Inge GyssensSenior Researcher and Professor of Infectious Diseases, Dept. of Internal Medicine, Radboud University Medical Center and DRIVE-AB partner

Inge C Gyssens, MD PhD is professor of Infectious Diseases at Hasselt University, Belgium and Head of the Department of Infectious Diseases & Immunity at Jessa Hospital, Hasselt, Belgium

She also has an appointment for research and teaching at the

Department of Medicine, Radboud University Medical Center,

Nijmegen, the Netherlands.

She obtained her MD from Antwerp University, Belgium, where

she completed her training in Internal Medicine after serving

as a tropical doctor in north west Africa for 5 years. She trained

in Infectious Diseases at Leiden University and obtained her

PhD degree from Nijmegen University. From 1992 to 2007

she was at Erasmus University Medical Center, Rotterdam

and was Director of the Infectious Diseases Fellowship

Training Program.

Professor Gyssens’ research focuses on optimizing antimicrobial

therapy, and innate immunity of infectious disease. She has

conducted audits and intervention studies in Antimicrobial

Stewardship in a range of countries. She is currently work package

leader of two European projects, the Innovative Medicines

Initiative (IMI) DRIVE-AB, and the Horizon 2020 FAPIC (Fast Assay

for Pathogen Identification and Characterisation) project. She

served as chair of the ESCMID Study Group for Antibiotic Policies,

and as National Delegate for the focal point of Antimicrobial

Resistance Netherlands, European Centre for Disease Prevention

and Control (ECDC).

Notes

DRIVE-AB PANELLIST

Yehuda CarmeliProfessor of Medicine, Tel-Aviv Medical Center and DRIVE-AB partner

Yehuda Carmeli, MD, MPH, professor of medicine, Tel Aviv University, is the Head of the Israeli National Center for Antibiotic Resistance, and the chief of the Division of Epidemiology at the Tel Aviv Medical Center, in Tel Aviv, Israel

Dr. Carmeli received his MD degree from Ben Gurion University,

Israel and his MPH degree at Harvard School of Public Health.

He served his residency at Hadassah Medical Center, Hebrew

University, Jerusalem, and then served as a fellow in Medicine at

Massachusetts General Hospital, Boston. Dr. Carmeli completed

his fellowship in Infectious Diseases at Beth Israel Deaconess

Medical Center, Boston, MA. His primary research interest is

the epidemiology of resistance to antibiotics. Dr. Carmeli is

the author of over 250 research articles, the recipient of

multiple research grants and awards, and member of editorial

board of major journals in the fields of Infectious Diseases

and antibiotic research.

Notes

DRIVE-AB PANELLIST



Marc SprengerDirector, Antimicrobial Resistance Secretariat, World Health Organization

Dr Marc Sprenger, a medical doctor and expert in infectious diseases, epidemiology and global health, has been Director of the antimicrobial resistance secretariat at the World Health Organization in Geneva since September 2015 and responsible for the coordination of an Organization-wide implementation of the Global Action Plan AMR

From 2010 to 2015 Sprenger was Director of the European Centre

for Disease Prevention and Control (ECDC).

From 2003 to 2010 Sprenger was Director General of the Dutch

National Institute for Public Health and the Environment (RIVM).

As Director of Health (1999-2003) of the Dutch National

Healthcare Insurance Board, he was tasked with advice on health

care system and insurance issues, including reimbursement of

new pharmaceuticals.

As head of the Centre for Infectious Disease Epidemiology, RIVM

(1993-1999) he was responsible for setting up a new centre of

national coordination of infectious diseases epidemiology and

initiated the European Antimicrobial Resistance Surveillance

System (EARSS).

Dr Sprenger has studied General Medicine at University of

Maastricht, specialized as medical microbiologist at Erasmus

Medical Center (Rotterdam) and obtained a PhD in Epidemiology

at Erasmus University.

Notes

DRIVE-AB PANELLIST

Dominique MonnetHead of Programme Antimicrobial Resistance & Healthcare-associated Infections, European Centre for Disease Prevention and Control (ECDC)

Dominique L. Monnet joined ECDC in October 2007 to lead ECDC’s Disease Programme on Antimicrobial Resistance and Healthcare-Associated Infections

He also represents ECDC in the EU-US Transatlantic Task Force on

Antimicrobial Resistance (TATFAR).

Before joining ECDC, he worked in French hospitals, at the US

Centers for Disease Control and Prevention (1993-1995) and

at the Danish Statens Serum Institut (1997-2007) where he

was coordinating surveillance of antimicrobial resistance and

antimicrobial consumption in humans in Denmark.

His research interests include surveillance of antimicrobial

resistance and antimicrobial consumption, the relationship

between consumption of antimicrobials and resistance, and the

factors that affect antimicrobial usage, both in hospitals and in

primary care.

DRIVE-AB PANELLIST


Notes

24


Arjun SrinivasanAssociate Director for Infection Prevention Programs, Centers for Disease Control and Prevention

Dr Arjun Srinivasan is the Associate Director for Healthcare Associated Infection Prevention Programs in the Division of Healthcare Quality Promotion at the Centers for Disease Control and Prevention. He is board certified in Infectious Diseases

Before coming to CDC he was as Assistant Professor of Medicine

in the Infectious Diseases Division at the Johns Hopkins School

of Medicine where he was the founding director of the Johns

Hopkins Antibiotic Management Program and the associate

hospital epidemiologist. His primary responsibilities include

oversight and coordination of efforts to eliminate healthcare

associated infections. His research and investigative areas of

concentration include outbreak investigations, infection control,

multi-drug resistant gram negative pathogens and antimicrobial

use. From 2006-2010, he led the CDC’s healthcare outbreak

investigations team. In 2008, he assumed the medical directorship

of a new CDC campaign called “Get Smart for Healthcare” which

is designed to improve the use of antimicrobials in in-patient

healthcare facilities. Dr. Srinivasan has published more than 70

articles in peer-reviewed journals on his research in healthcare

epidemiology, infection control and antimicrobial use and

resistance.

Notes

DRIVE-AB PANELLIST

Betuel SigauquePaediatrician and a Senior Researcher, Manhiça Health Research Centre, Mozambique

Dr Betuel Sigaúque (MD. PhD) - is a Paediatrician and a Senior Researcher at Centro de Investigação em Saúde de Manhiça (CISM). Dr Sigaúque completed PhD in Public Health by the University of Barcelona in Spain. Additionally, he completed the Diploma in Tropical Medicine and Hygiene at the University of Liverpool, UK

Beyond the Paediatric clinical care, Dr Sigaúque is interested in

biomedical research that is linked to solving the Public Health

problems in the area of infectious diseases and antimicrobial

resistance. Dr Sigaúque is leading the Acute Respiratory &

invasive Bacterial Infections research unit at CISM, and he is the

national focal point in Antimicrobial resistance in Mozambique.

He is leading the development of the National Action Plan on

AMR, with support from Center for Disease Dynamics, Economics

& Policy in US. Dr Sigauque, he is also responsible for the national

monitoring and evaluation of the impact and effectiveness of

pneumococcal conjugate vaccine and chair of Mozambique’s

Working Group for the Global Antibiotic Resistance Partnership

GARP. He has extensive experience in research and has more than

50 publications in peer-reviewed journals.

DRIVE-AB PANELLIST


Notes

26


Jean-Pierre PaccaudBD Director, Drugs for Neglected Diseases initiative, and Global Antibiotic Research and Development partnership

Dr Jean-Pierre Paccaud is responsible for DNDi’s business development activities, including opportunity identification, contract structure and negotiations, and alliance management. Prior to joining DNDi, he served as Head of Business Development for R&D products at OM Pharma

Dr. Paccaud also notably founded and led Athelas SA, a startup

company active in the field of anti-bacterial drug discovery,

until its merger with Merlion Pharmaceuticals. Before taking on

entrepreneurial challenges in industry, Dr. Paccaud spent more

than 15 years in academia, working in immunology, diabetes, and

cell biology.

Trained as a molecular and cellular biologist, Jean-Pierre Paccaud

completed his post-doctoral studies at the University of California

at Berkeley, and earned his PhD at the University of Geneva School

of Medicine.

Notes

DRIVE-AB PANELLIST

Shiva Dustdar Head of Division, Innovation Finance Advisory, Advisory Services Department, European Investment Bank

Shiva Dustdar heads the Innovation Finance Advisory Division in the EIB. She has been at the EIB since 2003, first in Risk Management, then in its Lending Directorate financing higher risk, innovative projects before joining the Advisory Services Department

Before EIB, Shiva was Director of High Yield at Fitch Rating

Agency developing its European High Yield rating business and

worked in the M&A Advisory and Emerging Markets Investment

Banking Group at J.P. Morgan in New York and London.

Shiva holds a BA in Economics from Columbia University and an

Executive MBA from London Business School (LBS). In 2000, Shiva

co-founded the European High Yield Association (EHYA), which

is now part of the Association for Financial Markets in Europe

(AFME). In 2006, Credit Magazine nominated Shiva to its Top 50

Women in Credit.

Notes

DRIVE-AB PANELLIST



Florence SejourneCEO, Da Volterra

Seasoned Biotech Entrepreneur with scientific, management and business background trained in France (Mines Paritech) and the USA (UofI@Chicago)

Florence co-founded Genfit (Euronext GNFT), a leading public

EU biotech company in the field of metabolic and inflammatory

diseases with a particular focus on the liver and gastroenterology,

where she had been member of the Board of Directors, Chief

Operating Officer, Chief Business Officer and Alliance & Grant

Manager for 10 years. Florence brings to Da Volterra the

experience of successful entrepreneurial adventures, with the

capacity to set up and lead a highly professional organization

from early research to late stage clinical development and market

access, the ability to raise funds and non-dilutive public grants, to

structure and negotiate deals with pharmaceutical and biotech

Companies in a highly competitive international environment.

From 2008, Florence has been interested in building creative

business models to face the economic issues of innovation in the

antimicrobial resistance and bacterial infections. As Da Volterra’s

CEO, she initiated the BEAM Alliance, which represents 49

European biopharmaceutical companies involved in developing

innovative products to tackle antimicrobial resistance from 12

countries.

Notes

DRIVE-AB PANELLIST

Joe LarsenDeputy Director, Biomedical Advanced Research and Development Authority

Dr Joe Larsen is acting Deputy Director of the Biomedical Advanced Research Development Authority (BARDA). In that role, he oversees a $2.8B fund for the development and procurement of medical products for use during public health emergencies

From 2014-2016, Joe served as the Deputy Director of BARDA’s

Chemical, Biological, Radiological, and Nuclear Medical

Countermeasure Division. He is also the BARDA lead for the

Obama Administration’s Initiative on combating antibiotic

resistant bacteria and has chaired intergovernmental working

groups on research and development and economic incentives for

antibacterial drug development. Previously Dr. Larsen served as

Chief of the Broad Spectrum Antimicrobials program at BARDA.

In that role, he oversaw a portfolio of approximately $1.2B in

programs that support the development of novel antibacterial and

antiviral drugs. Dr. Larsen received his PhD in Microbiology from

the Uniformed Services University of the Health Sciences and his

BA with honors from the University of Kansas.

Notes

DRIVE-AB PANELLIST



John RexSeniorVicePresidentandChiefStrategyOfficerAstraZeneca

John H. Rex MD is Senior Vice President and Chief Strategy Officer for AstraZeneca Infection, a Non-Executive Director of F2G, Ltd. and Adenium Biotech ApS, Expert-in-Residence at the Wellcome Trust, and a member of the US Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria

Dr. Rex thus brings a global perspective to the challenge of

AMR as well as both small and large pharmaceutical company

experience. He is one of two Industry-based cofounders of the

Innovative Medicines Initiative’s New Drugs for Bad Bugs program

bringing Industry and Academic collaborators together on a range

of antibiotic discovery and development projects.

Notes

DRIVE-AB PANELLIST

Marc MendelsonPresident, Federation of Infectious Diseases Societies of Southern Africa

Marc Mendelson is Professor of Infectious Diseases and head of Division of Infectious Diseases & HIV Medicine at the University of Cape Town, South Africa

He is Chair of the Ministerial Advisory Committee on Antimicrobial

Resistance (AMR), South African lead for the Global Health

Security Agenda Prevent-1 AMR Work Package, Co-Chair of the

South African Antibiotic Stewardship Programme, and co-author

of the South African National AMR Strategic Framework. He is

the current President of the Federation of Infectious Diseases

Societies of Southern Africa (FIDSSA), and President-Elect of the

International Society for Infectious Diseases (ISID).

Notes

DRIVE-AB PANELLIST



Manica BalasegaramExecutive Director, Médecins Sans Frontières Access Campaign

Dr Manica Balasegaram is a medical doctor who trained at the University of Nottingham, United Kingdom. He received further post-graduate training in internal and emergency medicine in the UK and Australia. He joined MSF in 2001, working as a doctor in the field in several countries in Sub-Saharan Africa and Southern Asia

After gaining significant operational research experience, Dr

Balasegaram became Head of the Manson Unit – a London-based

medical research and implementation arm of MSF – in 2005.

He then joined MSF partner organisation Drugs for Neglected

Diseases initiative (DNDi) in 2008, where he worked for four and

a half years, finishing as DNDi’s Head of Leishmaniasis Clinical

Development Team before joining the Access Campaign.

Dr Balasegaram has worked extensively on issues around access

to medicines, with a particular focus on tropical and neglected

diseases; to this end he has considerable training in both Public

Health and Tropical Medicine from the London School of Hygiene

and Tropical Medicine, with significant work experience in

both areas. He also has substantial experience in clinical trials

and drug development working as a site investigator, principal

investigator and project manager.

Notes

DRIVE-AB PANELLIST

Wiebke Antonia LöbkerPharmD,PhD,ScientificAdvisor,PharmaceuticalsDeparment,Federal Joint Committee (G-BA), Germany

Wiebke Antonia Löbker has a degree in pharmaceutical science, Freie Universität Berlin, Germany

She is a research fellow in the field of drug metabolism with a

PhD from the Institute of Pharmacology and Toxicology at the

Freie Universität. Since 2011 she has been Scientific Advisor,

Pharmaceuticals Department, Federal Joint Committee (G-BA),

with a focus on early benefit assessment of new pharmaceuticals

according to German Social Code Book V

DRIVE-AB PANELLIST


Notes


Christian Brun-BuissonChair, Advisory Board for the French national programme for Prevention and Control of Health-Care Associated Infections, Ministry of Health, France

Prof. Christian Brun-Buisson is professor of medicine and Intensive Care at University Paris-Est Créteil, and director of the Medical Intensive Care Unit and Infection Control Unit at Henri Mondor University Hospital, Créteil, Fr

He chaired the Infection Control Committee of the Paris public

hospitals consortium (AP-HP) and also chairs (2005-2010, 2012-

2015) the Advisory Board for the French national programme for

Prevention and Control of Health-Care Associated Infections at

the MoH. Prof. Brun-Buisson has served on the editorial board

of several medical journals, including JAMA, AJRCCM, Intensive

Care Med, and ICHE. His major fields of interest, reflected in

over 300 peer-reviewed publications, are the epidemiology

and management of sepsis, hospital-acquired infections and

antimicrobial resistance.

Notes

DRIVE-AB PANELLIST

Julie GerberdingM.D., M.P.H., Executive Vice President, Strategic Communications, Global Public Policy, and Population Health, MSD

Dr Julie Gerberding is Executive Vice President, Strategic Communications, Global Public Policy, and Population Health at MSD, where she also has responsibility for the MSD for Mothers program and the MSD Foundation

Julie joined MSD in 2010 as President of MSD Vaccines and was

instrumental in increasing access to vaccines worldwide and

making them more affordable for the people who need them

most. She previously served as Director of the U.S. Centers for

Disease Control and Prevention (CDC) from 2002-2009. In this

position, she led the agency through more than 40 emergency

responses to public health crises, including anthrax bioterrorism,

SARS, and natural disasters. She also advised governments around

the world on urgent issues such as pandemic preparedness, AIDS,

antimicrobial resistance, tobacco, and cancer. Dr. Gerberding

is a passionate global health advocate and is committed to

eliminating cervical cancer and other HPV cancers around the

world. She serves on the Boards of the Accordia Global Health

Foundation and the MSD Wellcome Trust Hilleman Laboratories,

a non-profit joint venture to develop new vaccines and

technologies appropriate to developing countries. Dr. Gerberding

received her Bachelor and M.D. degrees from Case Western

Reserve University and is also an Associate Adjunct Professor

of Medicine (Infectious Diseases) at University of California San

Francisco. Most recently she has served as a medical volunteer

at St. Boniface Hospital in Fond-des-Blancs, Haiti.

Notes

DRIVE-AB PANELLIST



Ursula TheuretzbacherFounder and Principal, Center for Anti-Infective Agents in Vienna, Austria, DRIVE-AB partner

Dr Ursula Theuretzbacher is founder and principal of the Center for Anti-Infective Agents in Vienna, Austria, since 1988. A microbiologist by training, she dedicated her professional life to antibacterial drug R&D as well as optimized usage of these drugs

She is currently work package leader in the multinational

collaborative EU funded project AIDA (Re-developing old

antibiotics) and in the multinational public-private partnership

project DRIVE-AB (Incentivizing antibacterial drug R&D, funded by

the EU Innovative Medicines Initiative=IMI) and partner in the IMI

project COMBACTE-MAGNET (Developing new molecules against

Gram-Negative Infections). Ursula Theuretzbacher is currently

President of the Society of Anti-Infective Pharmacology (ISAP)

and Founding President of the ESCMID (European Society

of Clinical Microbiology and Infectious Diseases) PK/PD of

Anti-Infectives Study Group (EPASG). She is chair of a policy

and scientific study group of the International Society of

Chemotherapy (ISC), Member of the Executive Committee of the

International Society of Infectious Diseases (ISID) and member

of the ECCMID Programme Committee.

Notes

DRIVE-AB PANELLIST


Notes

DRIVE-AB (www.drive-ab.eu) is supported by the Innovative Medicines Initiative (IMI) Joint Undertaking (www.imi.europa.eu), resources for which are provided by a financial contribution from the European Union’s Seventh Framework Programme (FP7/2007-2013) and in kind contributions from member companies of EFPIA (European Federation of Pharmaceutical Industries and Associations). DRIVE-AB is part of the IMI’s New Drugs for Bad Bugs (ND4BB) programme

Antimicrobial Resistance is a threat that is evolving slowly but

progressively, jeopardizing the health of all people. Antimicrobial

Resistance is therefore a top priority on the Health Agenda during

the Dutch EU-presidency in the first half of 2016. In February,

the Netherlands organized the first One Health Ministerial

conference on AMR. Because the Netherlands believes the One

Health approach, when all disciplines work together, is crucial in

combating Antimicrobial Resistance.

This conference is generously supported by the Dutch Ministry of Health, Welfare and Sport.

www.drive-ab.eu

drie ab re-investment in r&d and responsible...

Documents